Pitfall in the Diagnosis of an Aggressive Adrenal Mass with Prominent Hirsutism: A Case Report

Here, we present the case of a 74-year-old woman with clinically prominent hirsutism and a large adrenal mass where the clinical diagnosis was inconsistent with the histological appearance. Her hormonal evaluation showed normal androgens with slightly inadequate cortisol suppression upon dexamethasone test but normal 24-h urinary free cortisol. Abdominal computed tomography (CT) imaging showed a large inhomogeneous mass of the left adrenal and the FDG PET/CT scan revealed hypermetabolic foci in the right upper lobe of the lung, in hilum lymph nodes, and in the soft tissue in proximity to the right femoral neck. The cytological examination of a biopsy from the pulmonary lesion showed a highly malignant neoplasm of unknown origin, and left adrenalectomy, nephrectomy, and splenectomy were performed. The pathologists reported infiltration of the adrenal by an undifferentiated carcinoma of unknown origin. Due to the clinical suspicion of adrenocortical carcinoma (ACC), a mitotane therapy along with hydrocortisone substitution was directly initiated, and the patient also received 6 cycles of chemotherapy. However, the patient’s condition deteriorated quickly, and she died. Upon availability of steroidogenic factor-1 staining, the positivity of the resected tumor could be documented postmortem, confirming the diagnosis of an ACC. Taken together, this case underlines the difficulties in the differential diagnosis of aggressive adrenal masses.
1. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2009;23:273– 89. [CrossRef]
2. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366:2189–97. [CrossRef]
3. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008;113:3130–6. [CrossRef]
4. Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg 2006;202:423–30. [CrossRef]
5. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev 2014;35:282– 326. [CrossRef]
6. Enriquez ML, Lal P, Ziober A, Wang L, Tomaszewski JE, Bing Z. The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms. Appl Immunohistochem Mol Morphol 2012;20:141–5.
7. Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1476–90. [CrossRef]